Biomarkers as Predictors of Recurrence following Curative Resection for Pancreatic Ductal Adenocarcinoma: A Review | Zendy

Sylvester N. Osayi | Zendy; Mark Bloomston | Zendy; C. Max Schmidt | Zendy; E. Christopher Ellison | Zendy; Peter Muscarella | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Biomarkers as Predictors of Recurrence following Curative Resection for Pancreatic Ductal Adenocarcinoma: A Review

Author(s) -

Sylvester N. Osayi,

Mark Bloomston,

C. Max Schmidt,

E. Christopher Ellison,

Peter Muscarella

Publication year - 2014

Publication title -

biomed research international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.772

H-Index - 126

eISSN - 2314-6141

pISSN - 2314-6133

DOI - 10.1155/2014/468959

Subject(s) - medicine , pancreatic ductal adenocarcinoma , biomarker , pancreatic cancer , adenocarcinoma , curative treatment , oncology , disease , surgical resection , cancer , biology , biochemistry

Pancreatic ductal adenocarcinoma (PDA) is the fourth most common cancer causing death in the United States. Early tumor recurrence is an important contributor to the dismal prognosis. The availability of an accurate prognostic biomarker for predicting disease recurrence following curative resection will be beneficial for patient care. Most of the currently studied biomarkers remain in the investigational phase, with CA 19-9 being the only biomarker currently approved by the FDA. Herein, we review the utility of CA 19-9 and other investigational cellular, gene, and molecular tumor markers for predicting PDA recurrence following curative surgical resection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research